Biotech Coronavirus

AbbVie Infectious Disease Exec Jumps Ship To COVID Antiviral Biotech

AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea Pharmaceuticals.

The Boston-based private biotech landed a huge $215 million series D financing round in March, which it is using toward a phase 2 trial of its oral purine nucleotide prodrug in people hospitalized with moderate cases of COVID-19.

That med, AT-527, works as a highly selective, orally administered direct acting antiviral, and is designed to inhibit the RNA polymerase enzyme, a key element in the replication machinery of RNA viruses. It’s hoped it can help beat out SARS-CoV-02, the virus causing COVID-19.

Read more…


Why The Coronavirus Pandemic Could Influence Biotech Stocks For Years To Come

The coronavirus pandemic will have a yearslong impact on biotech stocks, experts say, as investors cast aside common concerns about biotech companies and focus on the industry battle to develop winning Covid-19 treatments or vaccines.

Fervor over the race for the first coronavirus vaccine has led to skyrocketing valuations for previously unknown biotech stocks. Leaders so far in the process include Moderna (MRNA), BioNTech (BNTX) and Inovio Pharmaceuticals (INO).

Read more…

Medical Syringe & Vaccine

Pence Talks Vaccine Development at NC Biotech Center

Vice President Mike Pence discusses the coronavirus vaccine development effort at the N.C. Biotechnology Center with managers of a company conducting clinical trials on a vaccine candidate.

Read more…

Antibody Test

Austin Biotech Companies Get Emergency Approval For Coronavirus Antibody Tests

Two Austin-based biotechnology companies are shifting gears to speed up development of testing technology in the face of the coronavirus pandemic, aiming to expand testing and fuel research related to COVID-19.

Babson Diagnostics and Luminex Corporation have developed and received approval for blood-based serology tests, which can determine the presence of antibodies to COVID-19, the disease caused by the virus, even after a person has recovered.

Read more…

Biotech Concept

President Trump Visiting North Carolina To Tour Biotech Facility

MORRISVILLE, N.C. (WBTV) – The White House announced President Donald Trump will travel to North Carolina’s Research Triangle on Monday, July 27.

The president will visit a plant where potential coronavirus vaccine components are being developed.

The plant is in Morrisville, where President Trump will tour the FUJIFILM Diosynth Biotechnologies’ (FDB) Innovation Center.

Doctor with vaccine

Coronavirus Vaccines Get A Biotech Boost

Advances in technology are accelerating the search for drugs to arm the immune system against SARS-CoV-2.

In January, Barney Graham had a new vaccine ready for testing. Its target was the Nipah virus, which had caused respiratory illness and brain infections in past outbreaks in southeast Asia. Graham, a vaccinologist and deputy director at the US National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center in Bethesda, Maryland, was working with Moderna Therapeutics in Cambridge, Massachusetts, to build a type of vaccine never before approved for use. Unlike most vaccines, which are based on intact pathogens or their structural components, Moderna’s are built from a pathogen’s RNA. The team hoped that a vaccinated person’s cells would use the RNA to make protein, priming their immune system to generate a protective response.

Read more…

Biotech Coronavirus

San Diego Biotech’s Drug Shows Early Promise in Treating COVID-19 Pneumonia

San Diego biotech CalciMedica announced Thursday that an experimental drug it is testing to help COVID-19 patients stay off ventilators and recover sooner shows early signs of achieving both goals.

The key word is early. Results from the trial of 30 COVID-19 patients, 20 received the anti-inflammatory drug and 10 didn’t, are still being reviewed by a scientific journal. But the company released its findings online Wednesday after it says the journal encouraged it to do so.

Read more…


Covid-19 Vaccine Developed By US Biotech Firm Moderna Enters Final Stage Trial

US biotech firm Moderna said Tuesday it would enter the final stage of human trials for its Covid-19 vaccine on July 27, to test how well it protects people in the real world.

The announcement came as the results from an earlier trial intended to prove the vaccine was safe and triggered antibody production were published.

The upcoming Phase 3 trial will recruit 30,000 participants in the US, with half to receive the vaccine at 100 microgram dose levels, and the other half to receive a placebo.

Read more…

Doctor with Vaccine

German Biotech Sees Its Coronavirus Vaccine Ready for Approval by December

BioNTech CEO warns it could still take a decade to fight back virus that has now infected millions, despite global efforts and rapid progress.

BERLIN—The German biotech firm that has partnered with Pfizer Inc. to develop a coronavirus vaccine is confident it will be ready to seek regulatory approval by the end of the year, according to its chief executive.

Read more…

Medical Syringe & Vaccine

Maryland Biotech Companies At Forefront Of COVID-19 Vaccine Research

BALTIMORE (WJZ) — The worldwide race is on to find a COVID-19 vaccine, and Maryland is on the forefront of some of that research.

In the state, researchers at three companies are hard at work trying to create the first COVID-19 vaccine.

Among them is Emergent BioSolutions, a Global Life Sciences company headquartered in Gaithersburg, with facilities in Baltimore.

Among them is Emergent BioSolutions, a Global Life Sciences company headquartered in Gaithersburg, with facilities in Baltimore.

Read more…